Gut microbiota dysbiosis, sarcopenia, osteoporosis and osteosarcopenia in older people: A systematic review protocol.

Introduction: Sarcopenia and Osteoporosis are two prevalent conditions in the older population and are defined by low strength, muscle quality/volume and low Bone Mineral Density, respectively. When there is a concomitant presence of both, there is a novel musculoskeletal condition called Osteosarcopenia. These conditions adversely affect quality of life and elevate the risk of fractures, disability, and mortality among older individuals.

Bone Tissue Engineering With Chitosan, Carbon Nanotubes, and Hydroxyapatite Biomaterials Enriched With Mesenchymal Stem Cells: A Radiographic and Histological Evaluation in a Sheep Model Undergoing Ostectomy (Bone Tissue Engineering in a Sheep Model).

Comminuted fractures associated with tissue loss can adversely affect bone regeneration. Biomaterials enriched with mesenchymal stem cells (MSCs) employed for supporting osteosynthesis and potentiating osteoconduction are necessary to fill these bone defects. Natural compound biomaterials, similar to bone tissue, have been extensively tested in animal models for clinical use.

Acute Fatal Gastric Dilatation and Volvulus in a Captive Adult Linnaeus's Two-Toed Sloth () in Amazon Biome.

This study aims to report the dietary and daily management, clinical signs, complementary exams, and pathological findings related to an acute and fatal case of gastric dilatation and volvulus (GDV) in a captive Linnaeus's two-toed sloth () in the Amazon Biome. An adult female sloth, rescued after being electrocuted, was housed at the Wildlife Section of the Veterinary Hospital (WSVH) of the Institute of Veterinary Medicine (IVM) at the Universidade Federal do Pará (UFPA). It was fed a diverse diet that included animal protein, fruits, vegetables, and greens, with vitamin and mineral supplementation.

Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).

Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), with the aim of reviewing all the approved medications for the management of obesity in Brazil (sibutramine, orlistat, liraglutide, semaglutide and bupropion/naltrexone fixed dose), with the addition of tirzepatide, that is approved in other countries and likely approved soon in Brazil. The review is focused on efficacy, safety profile and the impact of drugs (based on existing studies) on different comorbidities.

Reassurance use and reassurance-related outcomes for low back pain in primary care: A scoping review.

We used a scoping review design to map the available evidence describing the use of reassurance in clinical practice, interventions to increase the delivery of reassurance, and reassurance-related outcome measures. We searched CINAHL, MEDLINE, EMBASE and Cochrane Central from inception to October 2024. Publications were included if they described the use of reassurance or reassurance-related outcome measures in patients with non-specific low back pain (LBP) presenting to primary care.